AstraZeneca, Johnson & Johnson, Regeneron, Sanofi, Berg, Icahn School of Medicine, Northwest Biotherapeutics
World Pharma News’ AstraZeneca Enters Co-promotion Agreement with Janssen in Japan for Innovative Prostate Cancer Treatment explains the agreement that was announced by AstraZeneca with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer.
Johnson & Johnson has submitted its new combination HIV medicine for approval according to PMLiVE. J & J Files HIV Combination in Europe outlines how approval is being sought for a fixed-dose tablet containing Prezista and Gilead’s cobicistat.
Reuter’s reports a new type of cholesterol drug from Regeneron Pharmaceuticals Inc. and Sanofi SA. Regeneron, Sanofi Drug Slashes Cholesterol in Late-Stage Trial emphasizes that when alirocumab, an injectable drug, is used by itself, it cut levels of “bad” LDL cholesterol almost in half in the first of a dozen late-stage trials of the medicine.
According to PBR, biopharmaceutical firm, Berg and the Icahn School of Medicine have entered into a pharmaceutical and diagnostic research and discovery deal to leverage the power of multi-omic biology and data analytics. Berg, Icahn School of Medicine Ink Deal for Drug Discovery Development details the partnership that is aimed at advancing treatment options for cancer, CNS and endocrine disorders, as well as inflammation and obesity, infections and rare disease patients.
Northwest Biotherapeutics has developed DCVax personalized immune therapies for cancer as reported by Fox News. Pharmaceutical Company Develops Personalized Immune Therapies for Cancer states that survival rates can be significantly extended without toxicity and with lower cost than most new cancer drugs.
